ES2093562B1 - Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. - Google Patents

Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.

Info

Publication number
ES2093562B1
ES2093562B1 ES09501035A ES9501035A ES2093562B1 ES 2093562 B1 ES2093562 B1 ES 2093562B1 ES 09501035 A ES09501035 A ES 09501035A ES 9501035 A ES9501035 A ES 9501035A ES 2093562 B1 ES2093562 B1 ES 2093562B1
Authority
ES
Spain
Prior art keywords
formation
systems
stabilization
colloidal systems
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09501035A
Other languages
English (en)
Other versions
ES2093562A1 (es
Inventor
Fernandez Maria Jose Alonso
Salve Pilar Calvo
Lopez Carmen Remunan
Jato Jose Luis Vila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Original Assignee
Universidade de Santiago de Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES09501035A priority Critical patent/ES2093562B1/es
Application filed by Universidade de Santiago de Compostela filed Critical Universidade de Santiago de Compostela
Priority to DE69634927T priority patent/DE69634927T2/de
Priority to AT96914215T priority patent/ATE330636T1/de
Priority to CA002195881A priority patent/CA2195881C/en
Priority to PCT/ES1996/000116 priority patent/WO1996037232A1/es
Priority to DK96914215T priority patent/DK0771566T3/da
Priority to US08/776,507 priority patent/US5843509A/en
Priority to PT96914215T priority patent/PT771566E/pt
Priority to EP96914215A priority patent/EP0771566B1/en
Publication of ES2093562A1 publication Critical patent/ES2093562A1/es
Application granted granted Critical
Publication of ES2093562B1 publication Critical patent/ES2093562B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Abstract

ESTABILIZACION DE SISTEMAS COLOIDALES MEDIANTE FORMACION DE COMPLEJOS IONICOS LIPIDO-POLISACARIDO. DESARROLLO DE UN PROCEDIMIENTO PARA PREPARAR SISTEMAS COLOIDALES QUE COMPRENDE INCORPORAR EN EL UNA COMBINACION DE UN AMINOPOLISACARIDO SOLUBLE EN AGUA Y DE CARGA POSITIVA Y UN FOSFOLIPIDO DE CARGA NEGATIVA. LOS SISTEMAS COLOIDALES (DENTRO DE LOS CUALES SE INCLUYEN NANOEMULSIONES, NANOCAPSULAS Y NANOPARTICULAS POLIMERICAS) SE ESTABILIZAN MEDIANTE LA FORMACION DE UN COMPLEJO IONICO, A NIVEL INTERFACIAL, CONSTITUIDO POR EL AMINOPOLISACARIDO Y EL FOSFOLIPIDO. LOS SISTEMAS COLOIDALES SE CARACTERIZAN POR PRESENTAR UN TAMAÑO DE PARTICULA INTERIOR A 1 MIM, UNA CARGA ELECTRICA POSITIVA Y UNA ESTABILIDAD EXCEPCIONAL DURANTE EL ALMACENAMIENTO. SON LIOFILIZABLES, LO QUE PERMITE SU CONSERVACION EN SECO Y SU POSTERIOR REDISPERSION MANTENIENDO LAS CARACTERISTICAS ORIGINALES DEL SISTEMA. OFRECEN INTERES COMO FORMAS FARMACEUTICAS PARA LA ADMINISTRACION DE MEDICAMENTOS POR LAS VIAS ORAL, TRANSDERMICA, TOPICA,OCULAR, NASAL Y VAGINAL. ADEMAS OFRECEN INTERES COMO FORMAS DE USO COSMETICO.
ES09501035A 1995-05-26 1995-05-26 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. Expired - Fee Related ES2093562B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES09501035A ES2093562B1 (es) 1995-05-26 1995-05-26 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
AT96914215T ATE330636T1 (de) 1995-05-26 1996-05-24 Stabilisation von kolloidalen systemen durch die bildung von ionischen lipid-polysaccharid- komplexen
CA002195881A CA2195881C (en) 1995-05-26 1996-05-24 Stabilization of colloidal systems through the formation of lipid-polysaccharide complexes
PCT/ES1996/000116 WO1996037232A1 (es) 1995-05-26 1996-05-24 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido
DE69634927T DE69634927T2 (de) 1995-05-26 1996-05-24 Stabilisation von kolloidalen systemen durch die bildung von ionischen lipid-polysaccharid-komplexen
DK96914215T DK0771566T3 (da) 1995-05-26 1996-05-24 Stabilisering af kolloidale systemer ved dannelsen af ioniske lipidpolysaccharidkomplekser
US08/776,507 US5843509A (en) 1995-05-26 1996-05-24 Stabilization of colloidal systems through the formation of lipid-polyssacharide complexes
PT96914215T PT771566E (pt) 1995-05-26 1996-05-24 Estabilizacao de sistemas coloidais pela formacao de complexos ionicos lipido-polissacarido
EP96914215A EP0771566B1 (en) 1995-05-26 1996-05-24 Stabilization of colloidal systems by the formation of ionic lipid-polysaccharide complexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09501035A ES2093562B1 (es) 1995-05-26 1995-05-26 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.

Publications (2)

Publication Number Publication Date
ES2093562A1 ES2093562A1 (es) 1996-12-16
ES2093562B1 true ES2093562B1 (es) 1997-07-01

Family

ID=8290513

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09501035A Expired - Fee Related ES2093562B1 (es) 1995-05-26 1995-05-26 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.

Country Status (9)

Country Link
US (1) US5843509A (es)
EP (1) EP0771566B1 (es)
AT (1) ATE330636T1 (es)
CA (1) CA2195881C (es)
DE (1) DE69634927T2 (es)
DK (1) DK0771566T3 (es)
ES (1) ES2093562B1 (es)
PT (1) PT771566E (es)
WO (1) WO1996037232A1 (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
FR2760641B1 (fr) * 1997-03-13 2000-08-18 Oreal Emulsion huile-dans-eau stable, son procede de fabrication et son utilisation dans les domaines cosmetique et dermatologique
DE19733625A1 (de) * 1997-07-28 1999-02-04 Lancaster Group Gmbh Dekorative kosmetische O/W-Emulsion
KR19990058599A (ko) * 1997-12-30 1999-07-15 손경식 이중 캡슐을 함유하는 화장료 조성물
DE19826503A1 (de) * 1998-06-13 1999-12-16 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen mit einem Gehalt an Chitosan und Phospholipiden
ATE293895T1 (de) * 1999-10-29 2005-05-15 Hunza Di Pistolesi Elvira E C Faserige lipo-ernährungskomplexe und diese enthaltende zusammensetzungen
FR2801811B1 (fr) * 1999-12-06 2002-05-03 Gerard Habar Procede de fabrication de microcapsules portant des charges cationiques
WO2001062376A1 (de) * 2000-02-23 2001-08-30 Henkel Kommanditgesellschaft Auf Aktien Mikro- und/oder nanokapseln
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
EP1324885A1 (en) 2000-10-02 2003-07-09 Kimberly-Clark Worldwide, Inc. Recording medium with nanoparticles and methods of making the same
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
AU2002245629A1 (en) * 2001-03-08 2002-09-24 Targesome, Inc. Stabilized therapeutic and imaging agents
US6673263B2 (en) 2001-07-26 2004-01-06 Ppg Industries Ohio, Inc. Compositions incorporating chitosan for paint detackification
US20040000329A1 (en) * 2001-07-26 2004-01-01 Albu Michael L. Compositions and methods for paint overspray removal processes
CA2462593A1 (en) * 2001-10-03 2003-04-10 Kam W. Leong Compositions for oral gene therapy and methods of using same
MXPA04006017A (es) * 2001-12-20 2005-06-08 Femmepharma Inc Suministro de farmacos por via vaginal.
EP1474108A2 (en) * 2002-01-09 2004-11-10 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20030176310A1 (en) * 2002-03-15 2003-09-18 Huang Robert Y.M. Chitosan/anionic surfactant complex membrane
ES2197836B1 (es) * 2002-06-28 2005-05-01 Consejo Sup. Investig. Cientificas Procedimiento para la preparacion de nano-emulsiones de tipo agua en aceite (w/o) por metodos de emulsificacion de condensacion.
US6780896B2 (en) * 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
JP2006515026A (ja) * 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド ***の疾患および障害の処置のための薬学的調製物
JP5026074B2 (ja) * 2003-08-20 2012-09-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 疎水性液体マトリクス中に拡散または分散した親水性化合物の抽出および濃縮の方法
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7879350B2 (en) 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7837663B2 (en) 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
WO2005041933A1 (en) * 2003-10-31 2005-05-12 Teva Pharmaceutical Industries, Ltd. Nanoparticles for drug delivery
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US8562505B2 (en) 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US20060003956A1 (en) * 2004-03-03 2006-01-05 Casadome David O Materials and methods for the derepression of the E-cadherin promoter
US7901707B2 (en) * 2004-03-15 2011-03-08 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
CN1311867C (zh) * 2004-09-27 2007-04-25 侯新朴 一种用于鼻腔给药的神经生长因子制剂
ES2259914B1 (es) * 2005-03-14 2007-06-16 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
EP1834635B1 (en) * 2006-03-13 2011-07-06 Advanced in Vitro Cell Technologies, S.L. Stable nanocapsule systems for the administration of active molecules
US7977103B2 (en) 2006-04-20 2011-07-12 Kimberly-Clark Worldwide, Inc. Method for detecting the onset of ovulation
CA2674078C (en) * 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US8778400B2 (en) * 2008-04-21 2014-07-15 University Of South Australia Nanoparticle-stabilized capsule formulation for treatment of inflammation
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
EP2451442A4 (en) 2009-07-09 2014-02-12 Oshadi Drug Administration Ltd MATRIX COMPOSITION COMPOSITIONS, METHODS AND USES
EP2361509A1 (en) 2010-02-15 2011-08-31 Nestec S.A. Liquid-filled protein-phosphatidic acid capsule dispersions
EP2364600A1 (en) 2010-02-18 2011-09-14 Nestec S.A. Liquid-filled chitosan-anionic liposoluble capsule dispsersions
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
US9326980B2 (en) * 2013-07-21 2016-05-03 Kimia Zist Parsian (Kzp) Method and system for synthesizing nanocarrier based long acting drug delivery system for buprenorphine
US9351932B2 (en) * 2014-07-21 2016-05-31 Kimia Zist Parsian (Kzp) Method and system for synthesizing nanocarrier based long acting drug delivery system for methadone
PL229276B1 (pl) 2015-07-17 2018-06-29 Univ Jagiellonski Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
WO2018146365A1 (es) 2017-02-09 2018-08-16 Universidade De Santiago De Compostela Particulas purificadas de polen y su uso para administrar nanosistemas
US11883401B2 (en) 2019-01-08 2024-01-30 Duke University Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
EP3914621A1 (en) 2019-01-21 2021-12-01 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
CA3146344A1 (en) 2019-05-03 2020-11-12 Singapore Health Services Pte. Ltd. Treatment and prevention of metabolic diseases
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
WO2023111196A1 (en) 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier

Also Published As

Publication number Publication date
PT771566E (pt) 2006-08-31
ATE330636T1 (de) 2006-07-15
DE69634927D1 (de) 2005-08-18
CA2195881A1 (en) 1996-11-28
ES2093562A1 (es) 1996-12-16
CA2195881C (en) 2006-09-12
DK0771566T3 (da) 2006-10-23
DE69634927T2 (de) 2008-05-15
WO1996037232A1 (es) 1996-11-28
US5843509A (en) 1998-12-01
EP0771566A1 (en) 1997-05-07
EP0771566B1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
ES2093562B1 (es) Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
Zimmer et al. Evaluation of pilocarpine-loaded albumin particles as controlled drug delivery systems for the eye. II. Co-administration with bioadhesive and viscous polymers
JP3323499B2 (ja) 正電荷粒子の油／水エマルジョン
EP0995435B1 (en) Aqueous suspension preparations with excellent redispersibility
Gurny et al. Ocular therapy with nanoparticulate systems for controlled drug delivery
Badawi et al. Chitosan based nanocarriers for indomethacin ocular delivery
US5962015A (en) Stabilized liposomes
Davies et al. Evaluation of mucoadhesive polymers in ocular drug delivery. II. Polymer-coated vesicles
US5585109A (en) Cosmetic delivery system for salicylic acid and process for preparation of same
US5275820A (en) Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
AU692460B2 (en) Bioadhesive emulsion preparations for enhanced drug delivery
JP3624418B2 (ja) リポソーム点眼液
AU1042495A (en) Microsphere drug delivery system
DK0808156T3 (da) Præparater omfattende nanopartikler af NSAID
EP0860166B1 (en) Nanoparticles based on hydrophilic polymers as pharmaceutical forms
WO2000009096B1 (en) Injectable formulations of nanoparticulate naproxen
CA2059403A1 (en) Use of Carrageenans in Topical Ophthalmic Compositions
JP2006052229A (ja) 皮膚への局所投与による上側表皮層の持続的な化粧品学的および／または製薬学的処置を提供する組成物
CA2236864A1 (en) Electrostatically charged nasal application device and process
KR20010081061A (ko) 수불용성 성분의 침착을 조절하기 위한 조성물 및 방법
CN104491867B (zh) 一种壳聚糖包裹载药蒙脱石的新型给药***的制备方法
JPS60204708A (ja) 化粧料用保湿剤
WO1998011874A1 (en) Pharmaceutical composition forming a gel
AU676911B2 (en) Topical ophthalmic pharmaceutical vehicles
WO1990010635A1 (en) Novel antiperspirant adduct compositions and process for making same

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19961216

Kind code of ref document: A1

Effective date: 19961216

FD2A Announcement of lapse in spain

Effective date: 20180806